[1] Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds) (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edition–summary document. Ann Oncol. 2008;9(4):614–622. https://doi.org/10.1093/annonc/mdm481.
[2] Breast Imaging Reporting & Data System (BI-RADS®), American college of radiology. https:// www.acr.org/Clini cal-Resources/Reporting-and-Data-Systems/Bi-Rads
[3] Linee guida carcinoma mammario in stadio precoce. Edizione 2021 aggiornata al 11/11/2021. AIOM-Airtum-Fondazione AIOM. http://www.aiom.it
[4] Eliyatkın N, Yalçın E, Zengel B, AktaÅŸ S, Vardar E (2015) Molecular classifcation of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. J Breast Health 11(2):59–66. https://doi.org/10.5152/tjbh.2015.1669
[5] 21. Porter GJ, Evans AJ, Cornford EJ, Burrell HC, James JJ, Lee AH, Chakrabarti J (2007) Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 188(3):676–683. https://doi.org/10.2214/AJR.05.1950
[6] Li J, Ivansson E, Klevebring D, Tobin NP (2016) Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes. Clin Cancer Res 46:8–31. https://doi.org/10.1158/1078- 0432.CCR-16-0967
[7] Boyd NF, Huszti E, Melnichouk O, Martin LJ, Hislop G, Chiarelli A, Yaffe MJ, Minkin S (2014) Mammographic features associatedwith interval breast cancers in screening programs. Breast Cancer Res 16(4):417. https://doi. org/10.1186/s13058-014-0417-7
[8] Peeters P, Verbeek AL, Hendriks J, Holland R, Mravunac M, Vooijs G (1989) The occurrence of interval cancers in the Nijmegen screening programme. Br J Cancer 59:929–932
[9] Olinder J, Johnson K, Åkesson A et al (2023) Impact of breast density on diagnostic accuracy in digital breast tomosynthesis versus digital mammography: results from a European screening trial. Breast Cancer Res 25:116. https://doi.org/10.1186/s13058-023-01712-6
[10] Gennaro G, Bucchi L, Ravaioli A et al (2024) The risk-based breast screening (RIBBS) study protocol: a personalized screening model for young women. Radiol med. https://doi.org/10.1007/s11547-024-01797-9
[11] Lee CI, Chen LE, Elmore JG (2017) Risk-based breast cancer screening: implications of breast density. Med Clin North Am 101(4):725–741. https://doi.org/10.1016/j.mcna.2017.03.005
[12] Meshkat B, Prichard RS, Al-Hilli Z, Bass GA, Quinn C, O’Doherty A, Rothwell J, Geraghty J, Evoy D, McDermottEW (2015) A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer. Breast 24(3):278–282. https://doi.org/10.1016/j.breast.2015.02.032. (Epub 2015 Mar 11)
[13] Bellio G, Marion R, Giudici F, Kus S, Tonutti M, Zanconati F, Bortul M (2017) Interval breast cancer versus screen-detected cancer: comparison of clinicopathologic characteristics in a single-center analysis. Clin Breast Cancer 17(7):564–571. https://doi.org/10.1016/j.clbc.2017.04.001. (Epub 2017 Apr 11)
[14] Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T, Younis T, Burns A, Caines J (2011) Comparison of clinicalpathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case–control study. Clin Breast Cancer 11(1):27–32. https://doi.org/10.3816/CBC.2011.n. 005
[15] Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, Martínez J, Macià F, Quintana MJ, Albanell J, Castells X (2010) Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona. Spain Cancer Causes Control 21(8):1155–1164. https://doi.org/10.1007/s10552- 010-9541-6. (Epub 2010 Mar 28)
[16] Holm J, Humphreys K, Li J, Ploner A, Cheddad A, Eriksson M, Törnberg S, Hall P, Czene K (2015) Risk factors and tumor characteristics of interval cancers by mammographic density. J Clin Oncol 33(9):1030–1037. https://doi. org/10.1200/JCO.2014.58.9986. (Epub 2015 Feb 2)
[17] Baré M, Torà N, Salas D, Sentís M, Ferrer J, Ibáñez J, Zubizarreta R, Sarriugarte G, Barata T, Domingo L, Castells X, Sala M (2015) Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat 154(2):403–415. https://doi. org/10.1007/s10549-015-3623-9. (Epub 2015 Nov 3)
[18] Li J, Ivansson E, Klevebring D, Tobin NP, Lindström LS, Holm J, Prochazka G, Cristando C, Palmgren J, Törnberg S, Humphreys K, Hartman J, Frisell J, Rantalainen M, Lindberg J, Hall P, Bergh J, Grönberg H, Czene K (2017) Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes. Clin Cancer Res 23(10):2584–2592. https://doi.org/10.1158/1078-0432. CCR-16-0967. (Epub 2016 Sep 1)
[19] Porter GJ, Evans A, Burrell HC, Lee A, Ellis I, Chakrabarti J (2006) Interval breast cancers: prognostic features and survival by subtype and time since screening. J Med Screen 13:115–122
[20] Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, Key CR (2000) Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92(9):743–749. https://doi.org/10.1093/jnci/92.9.743
[21] Pálka I, Kelemen G, Ormándi K et al (2008) Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol OncolRes 14:161–167. https://doi.org/10.1007/s12253-008-9010-7
[22] Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SØ, Foulkes WD, Akslen LA (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14(5):1108–1112. https:// doi.org/10.1158/1055-9965.EPI-04-0394